Afatinib Anticancer Drugs Oncology Pharmacology Physiotherapy


In this article we will discuss about Afatinib (Dosage Overview)

In this article, we will discuss about Afatinib (Dosage Overview). So, let’s get started.

Afatinib (GILOTRIF®) is a kinase inhibitor indicated for:

First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

Limitation of Use: Safety and efficacy of Afatinib (GILOTRIF®) were not established in patients whose tumors have resistant EGFR mutations.

Afatinib (GILOTRIF®) is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.


• Recommended dose: 40 mg orally, once daily
• For patient’s with Renal impairment: 30 mg orally, once daily in patients with severe renal impairment. Afatinib (GILOTRIF®) to be taken least 1 hour before or 2 hours after a meal.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.